Oral Semaglutide and Your Heart: What a New Look at the SOUL Trial Adds
Author
Date Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link

If you take a GLP-1 pill or you're thinking about one, you may wonder what it does for your heart. A new paper in JAMA Cardiology takes a fresh look at that question for Rybelsus, the semaglutide pill for type 2 diabetes.
If you have heart disease or diabetes, your prescriber is the best person to help you apply any of this to your own care. The new paper is promising news and fits years of GLP-1 heart research. It's a second look at one trial, though, so it can't settle anything on its own.
Who This Helps
This is for anyone taking Rybelsus or the Wegovy pill, or anyone who wants to know more about their medication. It's also for anyone who sees a health headline and wonders how much to trust it.
What was the SOUL trial?
SOUL was a large heart study of the semaglutide pill. It followed 9,650 adults with type 2 diabetes who also had heart disease, kidney disease or both (JAMA Cardiology).
Half took the pill, up to 14 mg a day. The other half took a placebo, a dummy pill with no medicine in it. People were followed for about four years.
The study tracked three serious problems: a heart attack, a stroke, or a death caused by heart or blood vessel disease. In this post, we call any of those a "heart event."
By the end, 12% of people on the pill had at least one heart event, compared with 13.8% on placebo (Rybelsus label).
The clearest difference was in heart attacks that people survived. Heart-related deaths were close between the two groups, so the study can't say the pill helps people live longer.
Based on SOUL, the FDA added a heart benefit to the Rybelsus label in 2025. It now covers adults with type 2 diabetes who are at high risk for heart events (Rybelsus label).
What does the new paper add?
The main SOUL result asked a yes-or-no question: did each person have a heart event during the study? If someone had a heart attack and then a stroke a year later, only the heart attack counted.
The new paper went back and counted every heart event, including repeats. Researchers call this kind of second look at a trial's data a secondary analysis.
Counting everything, people on the pill had 683 heart events, compared with 791 on placebo (JAMA Cardiology).
That's about 14% fewer, which is close to the main result. Most of that gap came from the first heart event each person had, which the main result had already counted.
Only 19 of the 108 fewer events were repeats. That's because repeat heart events were fairly rare.
About 2 in 100 people in the whole trial had more than one heart event. The pill group had fewer repeats, but there were too few of them to rule out chance.
Find a provider in your state
Answer a few questions and see live pricing from the providers that ship where you live.
How does this fit with other heart studies?
The main SOUL result lines up with a lot of earlier research.
- PIONEER 6 (2019): An earlier study of the same pill in about 3,200 people. It showed the pill didn't raise the risk of heart problems over about 16 months. It also found half as many heart-related deaths. That was a side result based on few deaths, though, and the much larger SOUL trial didn't repeat it (NEJM via PubMed).
- SELECT (2023): This tested the weekly Wegovy shot in people with heart disease and overweight or obesity who didn't have diabetes. Heart events happened in 6.5% of people on Wegovy, compared with 8.0% on placebo (NEJM via PubMed).
- A 2021 review: Across eight trials in people with type 2 diabetes, GLP-1 drugs cut heart events by about 14%, close to what SOUL found (Lancet Diabetes & Endocrinology via PubMed).
What does it mean if you take a GLP-1 pill?
If you take Rybelsus and you're 50 or older with heart or kidney disease, you're the closest match to the people in SOUL. This paper adds a little more support for the heart benefit already on your label. It hasn't changed the label or how you take the pill.
If you take the Wegovy pill for weight, SOUL applies to you less directly. SOUL only included people with diabetes, and the Wegovy pill is a different brand with a higher daily dose (Wegovy label).
The Wegovy pill's label does list a heart benefit for adults who already have heart or blood vessel disease and also have overweight or obesity. The only large heart study on that label is SELECT, the Wegovy shot study above.
We couldn't find a large heart study of the Wegovy pill itself. If heart protection is a big reason you'd choose the pill, ask your prescriber how much a shot study tells you about the pill. Our post on GLP-1 pills vs. shots covers other differences.
How do you judge a single study?
You can ask these questions about any new health study, including this one.
Was the question planned ahead of time? Researchers can look at trial data in many ways after the fact, and some results will look good by chance. The count of repeat heart events was planned in advance, so it's more trustworthy. A second count that also included deaths not related to the heart wasn't planned, so it's weaker evidence.
Was the trial built to answer this question? SOUL was designed to compare how many people had a heart event at all. The authors write that it "was not designed to test" differences in repeat events. That makes this paper useful, but less certain than the main result.
How big is the change for a real person? A "14% lower risk" can sound large. The NIH says it's best to focus on absolute risk, meaning how many people out of 100 are affected (NIH News in Health).
In SOUL, that works out to about 2 fewer people out of every 100 having a heart event over about four years. It's smaller than "14%" might make it sound, but a valid benefit.
Who was studied? The typical person in SOUL was 66, had lived with diabetes for about 15 years and already had heart or kidney disease. The results may not carry over to younger, healthier people, so ask your prescriber how they fit you.
Who paid for it? Novo Nordisk, which makes the pill, paid for SOUL, ran the numbers for this paper and helped design and write it. Three authors work for the company, and a fourth did during the study. That's common for drug trials and doesn't mean the results are wrong. Still, it helps to see results checked by teams with no ties to the company.
Do other studies agree? A result is more reliable when bigger studies repeat it. The PIONEER 6 death finding above is a good example of one that didn't hold up in a larger trial.
Final Takeaway
If heart health is part of why you take a GLP-1, talk with your prescriber about which option fits you best. This new look at SOUL counted every heart event, including repeats, and got about the same result as the main study. The repeat events on their own were too few to show a clear difference. If you take the Wegovy pill, ask how much the Wegovy shot study applies to you.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Frequently Asked Questions
Does Rybelsus lower the risk of heart attack and stroke?
For some people, it lowers the overall risk. In the SOUL trial, people with type 2 diabetes and heart or kidney disease had fewer heart events on Rybelsus than on placebo. The clearest drop was in heart attacks people survived. Strokes dropped only a little, and that could have been chance.
Does the Wegovy pill protect your heart?
The Wegovy pill's label includes a heart benefit for adults with heart disease and overweight or obesity. The heart study on the label tested the Wegovy shot. We couldn't find a large heart study of the pill itself.
What is a secondary analysis?
It's a look at extra questions using data from a trial built around a different main question. Some are planned in advance and some are added later. Either way, they're usually less certain than the trial's main result.
Is one study enough to change my treatment?
Usually not. It's best to look at whether other studies agree and to talk with your prescriber about how the results apply to you.
Find a provider in your state
Answer a few questions and see live pricing from the providers that ship where you live.
Keep Reading

The FDA is requiring a NAION warning on every GLP-1. How rare it is, which symptoms mean call right away, and why not to stop on your own.

A Nov 2026 study linked GLP-1s to 31% fewer new diabetes cases than metformin in adults with prediabetes. What it shows, limits, what to ask.

11% of US adults take a GLP-1 and half say it is hard to afford. The time-horizon math behind employer, Medicare and state coverage, in plain terms.
Categories
Written by
Lauren PescarusLauren Pescarus is a team member with GLP Winner, where she works on marketing, content creation, and operations. She has over 10 years' experience in the content creation space, including in the GLP-1 space, where she works to stay on top of access news, research updates, and lifestyle tips guided by science.